Trandolapril and Verapamil
Active ingredient: Trandolapril, Verapamil Hydrochloride
In short: Trandolapril and verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension .
What is Trandolapril and Verapamil used for?
Trandolapril and verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension.
This fixed combination drug is not indicated for the initial therapy of hypertension .
In using trandolapril and verapamil hydrochloride extended-release tablets, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk .
âš Boxed warning (FDA's strongest warning)
•
When pregnancy is detected, discontinue trandolapril and verapamil hydrochloride extended-release tablets as soon as possible.
•
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus .
Verapamil has a negative inotropic effect which, in most patients, is compensated by its afterload reduction (decreased systemic vascular resistance) properties without a net impairment of ventricular performance. In clinical experience with 4,954 patients, 87 (1.8%) developed congestive heart failure or pulmonary edema. Verapamil should be avoided in patients with severe left ventricular dysfunction (e.g., ejection fraction less than 30%, pulmonary wedge pressure above 20 mmHg, or severe symptoms of cardiac failure) and in patients with any degree of ventricular dysfunction if they are receiving a beta adrenergic blocker . Patients with milder ventricular dysfunction should, if possible, be controlled with optimum doses of digitalis and/or diuretics before verapamil treatment (Note interactions with digoxin under:
PRECAUTIONS
).
Trandolapril, as an ACE inhibitor, may cause excessive hypotension in patients with congestive heart failure .
Occasionally, the pharmacologic action of verapamil may produce a decrease in blood pressure below normal levels which may result in dizziness or symptomatic hypotension.
Trandolapril can cause symptomatic hypotension. Like other ACE inhibitors, trandolapril has only rarely been associated with symptomatic hypotension in uncomplicated hypertensive patients. …
Trandolapril and Verapamil dosage
The recommended usual dosage range of trandolapril for hypertension is 1 to 4 mg per day administered in a single dose or two divided doses. The recommended usual dosage range of verapamil hydrochloride sustained-release tablets for hypertension is 120 to 480 mg per day administered in a single dose or two divided doses.
The hazards of trandolapril are generally independent of dose; those of verapamil are a mixture of dose-dependent phenomena (primarily dizziness, AV block, constipation) and dose-independent phenomena, the former much more common than the latter. Therapy with any combination of trandolapril and verapamil will thus be associated with both sets of dose-independent hazards. The dose-dependent side effects of verapamil have not been shown to be decreased by the addition of trandolapril nor vice versa.
Rarely, the dose-independent hazards of trandolapril are serious. To minimize dose-independent hazards, it is usually appropriate to begin therapy with trandolapril and verapamil hydrochloride extended-release tablets only after a patient has either (a) failed to achieve the desired antihypertensive effect with one or the other monotherapy at its respective maximally recommended dose and shortest dosing interval, or (b) the dose of one or the other monotherapy cannot be increased further because of dose-limiting side effects.
Clinical trials with trandolapril and verapamil hydrochloride extended-release tablets have explored only once-a-day doses. The antihypertensive effect and or adverse effects of adding 4 mg of trandolapril once-a-day to a dose of 240 mg verapamil hydrochloride sustained-release tablets administered twice-a-day has not been studied, nor have the effects of adding as little of 180 mg verapamil hydrochloride sustained-release tablets to 2 mg trandolapril administered twice-a-day been evaluated. Over the dose range of verapamil hydrochloride sustained-release tablets 120 to 240 mg once-a-day and trandolapril 0.5 to 8 mg once-a-day, the effects of the combination increase with increasing doses of either component.
For convenience, patients receiving trandolapril (up to 8 mg) and verapamil (up to 240 mg) in separate tablets, administered once-a-day, may instead wish to receive trandolapril and verapamil hydrochloride extended-release tablets containing the same component doses.
Trandolapril and verapamil hydrochloride extended-release tablets should be administered with food.
Warnings & precautions
Do not take this medicine if: Trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in patients who are hypersensitive to any ACE inhibitor or verapamil.
Because of the verapamil component, trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in:
1.Severe left ventricular dysfunction .
2.Hypotension (systolic pressure less than 90 mmHg) or cardiogenic shock.
3.Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker).
4.Second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker).
5.Patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g. Wolff-Parkinson-White, Lown-Ganong-Levine syndromes) .
6.Patients taking flibanserin .
Because of the trandolapril component, trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme (ACE) inhibitor.
Do not co-administer aliskiren with trandolapril and verapamil hydrochloride extended-release tablets in patients with diabetes .
Trandolapril and verapamil hydrochloride extended-release tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer trandolapril and verapamil hydrochloride extended-release tablets within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor .
Trandolapril and verapamil hydrochloride extended-release tablets have not been evaluated in subjects with impaired hepatic function.
Since verapamil is highly metabolized by the liver, it should be administered cautiously to patients with impaired hepatic function. …
Trandolapril and Verapamil side effects
Trandolapril and verapamil hydrochloride extended-release tablets have been evaluated in over 1,957 subjects and patients. Of these, 541 patients, including 23% elderly patients, participated in U.S. controlled clinical trials, and 251 were studied in foreign controlled clinical trials. In clinical trials with trandolapril and verapamil hydrochloride extended-release tablets, no adverse experiences peculiar to this combination drug have been observed. Adverse experiences that have occurred have been limited to those that have been previously reported with verapamil or trandolapril. Trandolapril and verapamil hydrochloride extended-release tablets have been evaluated for long-term safety in 272 patients treated for 1 year or more. Adverse experiences were usually mild and transient.
Discontinuation of therapy because of adverse events in U.S. placebo-controlled hypertension studies was required in 2.6% and 1.9% of patients treated with trandolapril and verapamil hydrochloride extended-release tablets and placebo, respectively.
Adverse experiences occurring in 1% or more of the 541 patients in placebo-controlled hypertension trials who were treated with a range of trandolapril (0.5 to 8 mg) and verapamil (120 to 240 mg) combinations are shown below. …
About this medicine
Trandolapril and verapamil hydrochloride extended-release tablets combine a slow release formulation of a calcium channel blocker, verapamil hydrochloride, USP, and an immediate release formulation of an angiotensin converting enzyme inhibitor, trandolapril, USP.
Verapamil hydrochloride, USP is chemically described as benzeneacetonitrile, α [3-[[2-(3,4-dimethoxyphenyl) -ethyl] methylamino] propyl] -3,4-dimethoxy-α -(1-methylethyl)-, monohydrochloride, (±). Its molecular formula is C27H38N2O4 • HCl and its structural formula is:
Verapamil hydrochloride, USP is a white or practically white crystalline powder, with a molecular weight of 491.06 g/mol. It is soluble in water, freely soluble in chloroform, sparingly soluble in alcohol and practically insoluble in ether. It is practically odorless and has a bitter taste.
Trandolapril, USP is the ethyl ester prodrug of a nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, trandolaprilat. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 39bad727-af4c-4d20-933b-7f287e88099a. Read the full official label on DailyMed.
Related medicines
Amlodipine Lisinopril Metoprolol Hydrochlorothiazide Tamsulosin Carvedilol Potassium Chloride Spironolactone